A Phase I/II Study of the Combination of Venetoclax, Ponatinib and Corticosteroids in Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Lymphoid Blast Phase Chronic Myelogenous Leukemia
Latest Information Update: 15 May 2025
At a glance
- Drugs Ponatinib (Primary) ; Venetoclax (Primary) ; Corticosteroids; Dexamethasone; Dexamethasone; Rituximab
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 May 2025 Status changed from completed to discontinued. (The study was terminated early due to slow accrual and low level of interest both by the sponsor and by the department )
- 28 Jun 2024 Status changed from active, no longer recruiting to completed.
- 19 Jul 2023 Planned End Date changed from 31 Aug 2023 to 31 Aug 2024.